Mineralys Therapeutics, Inc.
MLYSMineralys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing medicines for diseases driven by dysregulated aldosterone.
Earnings
Next report
Aug 11, 2026 (In 1 week)EPS estimate-$0.57
Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Mineralys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing medicines for diseases driven by dysregulated aldosterone. The company's primary focus is on cardiorenal conditions, specifically targeting uncontrolled and resistant hypertension as well as related comorbidities like chronic kidney disease and obstructive sleep apnea.
Competitive position
A clinical-stage developer of a highly selective aldosterone synthase inhibitor with a submitted NDA and a focus on large-scale cardiorenal unmet needs.
GeographiesUnited States
Customer segmentsPatients, Healthcare providers
Business modelR&D intensive, Biopharmaceutical drug development
SuppliersClinical research organizations, Contract manufacturing organizations, Regulatory agencies (FDA)
CustomersSpecialty pharmacies, Hospitals, Cardiologists, Nephrologists
CountryUnited States of America
Listed2023
Employees28.0
CEOJon Congleton
SectorHealthcare
IndustryBiotechnology
Websitemineralystx.com
FilingsSEC EDGAR
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s market cap?
- Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of $2.4B and trades on NASDAQ.
- Who are Mineralys Therapeutics, Inc.'s competitors?
- Mineralys Therapeutics, Inc.'s key competitors include Unicycive Therapeutics, Inc. Common Stock, Lexicon Pharmaceuticals, Inc., Mannkind Corporation, and others. These companies compete in similar markets and product categories.
- Where is Mineralys Therapeutics, Inc. headquartered?
- Mineralys Therapeutics, Inc. is headquartered in United States of America and employs approximately 28 people. It has been publicly traded since 2023.